Cart
sales@molnova.com
DSM421
CAS No. 2011769-21-2
DSM421( —— )
Catalog No. M34228 CAS No. 2011769-21-2
DSM421 (DSM-421) is a dihydrodehydrogenase inhibitor (DHODH) that is in preclinical development as a potential treatment option for malaria and has shown activity against field isolates of both P. falciparum and P. vivax.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 318 | In Stock |
|
| 5MG | 273 | In Stock |
|
| 10MG | 372 | In Stock |
|
| 25MG | 563 | In Stock |
|
| 50MG | 742 | In Stock |
|
| 100MG | 977 | In Stock |
|
| 200MG | 1293 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDSM421
-
NoteResearch use only, not for human use.
-
Brief DescriptionDSM421 (DSM-421) is a dihydrodehydrogenase inhibitor (DHODH) that is in preclinical development as a potential treatment option for malaria and has shown activity against field isolates of both P. falciparum and P. vivax.
-
DescriptionDSM421 (DSM-421) is a dihydrodehydrogenase inhibitor (DHODH) that is in preclinical development as a potential treatment option for malaria and has shown activity against field isolates of both P. falciparum and P. vivax.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorDehydrogenase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2011769-21-2
-
Formula Weight358.27
-
Molecular FormulaC14H11F5N6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C=1N2C(=NC(C(C)(F)F)=N2)N=C(C)C1)C=3C=CC(C(F)(F)F)=NC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Mercaptopurine (6-MP...
Mercaptopurine (6-mercaptopurine; 6-MP) is an immunosuppressive drug.
-
SW209049
SW209049 is a stearoyl-CoA 9-desaturase inhibitor. SW209049 exhivits potent activity against H2122 cell with IC50 of 0.13uM.
-
MF-438
MF-438 is an effective and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor (EC50: 2.3 nM for rSCD1). In a mouse model, MF-438 shows an ED50 between 1 and 3 mg/kg.
